GlassScriptPhysician profile
Megan Leigh Webb
NPI 1447843669
$1,956.11
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $652 · 2023: $496 · 2024: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $582.39 | 2021-2024 | Ztlido |
| Braeburn INC. | $332.08 | 2023-2024 | Brixadi |
| Forte Bio-Pharma LLC | $288.80 | 2021-2024 | Prolate, Nalocet |
| Indivior INC. | $258.55 | 2021-2024 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.51 | 2022-2024 | Relistor |
| Valinor Pharma, LLC | $71.59 | 2024 | Movantik |
| Virtus Pharmaceuticals LLC | $64.13 | 2023-2024 | Levorphanol Tartrate |
| Collegium Pharmaceutical, INC. | $54.46 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $34.00 | 2024 | Horizant |
| Arbor Pharmaceuticals, INC. | $28.59 | 2021 | |
| Biodelivery Sciences International, INC. | $22.82 | 2021 | |
| Ibsa Pharma INC. | $20.19 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.